跳至主要内容
临床试验/NCT04439084
NCT04439084已完成不适用

COVID-19 in Patients With Chronic Liver Diseases

Stanford University23 个研究点 分布在 1 个国家目标入组 1,025 人开始时间: 2020年3月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,025
试验地点
23
主要终点
Liver-related mortality

研究概览

简要总结

This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed diagnosis of COVID-19
  • Personal history of either
  • Chronic hepatitis C
  • Chronic hepatitis B
  • Alcoholic liver disease
  • Non alcoholic liver disease
  • Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitis
  • Cryptogenic cirrhosis
  • Hepatocellular carcinoma

排除标准

  • Non-COVID-19 patient

结局指标

主要结局

Liver-related mortality

时间窗: 1 year

Death due to liver-related cause

All-cause mortality

时间窗: 1 year

Death due to any cause

Overall survival

时间窗: Up to 1 year

Patients will be assessed for this outcome for up to 1 year

Number of patients with hepatic decompensation

时间窗: Up to 1 year

Onset of hepatic decompensation due to COVID-19 disease; patients will be assessed for this outcome for up to 1 year

次要结局

  • Number of participants requiring mechanical ventilation(Up to 1 year)
  • Duration of hospitalization(Up to 1 year)
  • Length of intensive care unit (ICU) stay(Up to 1 year)
  • Number of patients requiring hospitalization(Up to 1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (23)

Loading locations...

相似试验